BIP Wealth LLC Boosts Eli Lilly Stake by 161%

Investment firm adds over 2,200 shares of pharmaceutical giant in Q4

Apr. 12, 2026 at 7:37am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up image of the intricate mechanical components and gears inside a pharmaceutical manufacturing facility, conveying the industrial power and scale of the pharmaceutical industry.BIP Wealth's increased investment in pharmaceutical giant Eli Lilly reflects broader institutional confidence in the company's ability to innovate and expand its drug pipeline.Indianapolis Today

BIP Wealth LLC increased its holdings in Eli Lilly and Company (NYSE: LLY) by 161.4% in the fourth quarter, according to a recent 13F filing with the SEC. The firm now owns 3,673 shares of the pharmaceutical company's stock, up from 1,405 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative medicines and therapies. This investment by BIP Wealth suggests the firm sees strong growth potential in Lilly's business and pipeline, which could signal broader confidence in the stock among institutional investors.

The details

BIP Wealth purchased an additional 2,268 shares of Eli Lilly in Q4 2025, bringing its total position to 3,673 shares worth approximately $3.95 million. The firm's increased stake in Lilly comes as the company continues to expand its drug portfolio and make progress on key pipeline programs.

  • BIP Wealth filed its 13F report for Q4 2025 on April 12, 2026.

The players

BIP Wealth LLC

An investment management firm that oversees over $5 billion in client assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and commercializes a wide range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

BIP Wealth's significant increase in its Eli Lilly position suggests the firm sees strong long-term growth potential in the pharmaceutical company's business. This could signal broader institutional confidence in Lilly's ability to continue innovating and expanding its drug pipeline.